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ABSTRACT
Introduction: Cognitive impairment (CI) is an important but an under-recognized extra-pulmonary
feature of chronic obstructive pulmonary disease (COPD). It is related to the burden of disability, worse
health outcomes, and impaired self-management.
Areas covered: CI includes deterioration of a wide range of cognitive functions, such as memory and
various executive functions. Risk of hospitalization might be higher in patients with COPD compared to
those without, with CI negatively impacting the wellbeing of patients with COPD. Disease-specific
factors such as hypoxemia and inflammation, lifestyle factors such as dietary insufficiencies and lack of
physical activity, and comorbidities such as obstructive sleep apnea and depression are likely to
synergistically contribute to the development of CI in COPD. Tailored interventions can possibly
improve CI in COPD, but this needs further investigation.
Expert commentary: Further research is warranted involving the optimization of neuropsychological testing
for screening and outcome assessment, longitudinal studies to investigate the development of CI in COPD
over time, and randomized clinical trials to test the feasibility and efficacy of promising interventions.
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1. Introduction
Chronic obstructive pulmonary disease (COPD) is a chronic
lung disease characterized by persistent respiratory symptoms
and airflow limitation due to airway and/or alveolar abnorm-
alities [1]. It is well established that common extra-pulmonary
comorbidities such as heart failure, osteoporosis, and muscle
wasting contribute significantly to the disease burden [2].
Moreover, recent research shows that cognitive impairment
(CI) is also a common and important, yet under-investigated
comorbidity [3]. This review will discuss various aspects related
to CI in COPD: its prevalence and characteristics, related health
outcomes, determinants, and possible interventions to main-
tain or improve cognitive functioning in patients with COPD.
2. Cognitive functioning
Cognition can be defined as any brain function that enables an
individual to perceive, register, store, retrieve, and use information
in order to adapt behavior to new situations and function in our
environment [4]. Cognition consists of many separate domains,
including memory, working memory, and attention [5].
Cognition is organized hierarchically and different cognitive
functions can be classified as ‘lower’ or ‘higher’ [6] (see
Figure 1). The lower functions form the basis for the higher
functions, including the executive functions such as inhibition
(choosing an option that is more rewarding in the longer term
instead of the more immediately satisfying option when pre-
sented with a choice, for example, refusing the attempt to
smoke a cigarette) and cognitive flexibility (being able to
swiftly shift mental resources, for example, changing the
type of physical activity undertaken in case of weather
changes) [7]. Executive functioning in turn underlies even
more complex processes such as problem-solving and deci-
sion-making, for example, when and how to undertake action
in case of increased symptom severity (e.g., disease exacerba-
tion or unintended weight loss).
Specific brain areas do not exclusively perform a single task,
but many brain areas are specialized for certain types of tasks
(see Figure 2). The language and memory systems are largely
located in the temporal lobe, whereas the higher-order func-
tions such as inhibition, cognitive flexibility, reasoning, and
decision-making are processed in the frontal lobe.
Subcortical structures are located within the brain, including
the hippocampus, which plays a central role in memory
encoding; the limbic system, including the amygdala and
cingulate cortex, which are involved in fear and pain proces-
sing; and the basal ganglia, including the caudate nucleus,
which is involved in movement but also in learning and
remembering [8].
Brain damage, for instance, caused by brain atrophy or
degeneration, can contribute to the development of CI. This
is an inevitable part of aging, but acute and chronic disease
can accelerate it. In the initial stages of CI development,
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impairments are noticeable, but not severe enough to impair
activities of daily living; a stage called mild cognitive impair-
ment (MCI) [5]. MCI often, but not always, involves impair-
ments in memory rather than in other domains [9], and it may
progress into Alzheimer’s disease [9] or remain stable [10].
3. Cognitive impairment in COPD
Patients with COPD display impairment in cognitive
domains as diverse as attention, executive functioning
[3,11–13], (visual) memory and reproduction [14,15], pro-
blem-solving, concentration, logical and abstract reasoning,
planning, coordination, and organization [3]. Thus, the pat-
tern of impairments is diffuse, and not every patient is
affected or suffers from CI to the same degree in different
cognitive domains [16]. This diffuse pattern resembles
aging-related cognitive deterioration and is consistent with
the view of CI in COPD as a manifestation of accelerated
aging [3]. On the other hand, patients with Alzheimer’s
disease or other dementias show a much more specific
pattern of CI.
3.1. Prevalence
3.1.1. Cross-sectional studies
A recent meta-analysis pooled 14 studies investigating the
prevalence of CI in COPD patients [17]. The average prevalence
of any CI (5 studies, N = 2,995) was 32%. MCI was present in 25%
of patients (11 studies, N = 4,663). Higher prevalence of CI was
associated with respiratory disease severity, dependence in
activities of daily living and poor quality of life [17].
Studies published after this meta-analysis (25 February 2016)
show an even higher prevalence of CI (see Tables 1, 2). Two
studies by Cleutjens et al. reported CI, determined by extensive
neuropsychological assessment, in 56.7% and 41.5% of patients
with COPD referred for pulmonary rehabilitation (PR) [18,19]. In
the former study, only 13.3% of non-COPD age-matched controls
suffered from CI. Pierobon et al. showed that the Montreal
Cognitive Assessment (MoCA) score of 9.5% of patients admitted
Figure 1. A hierarchical view of cognitive processes. Adapted from Cleutjens et al. [4].
Figure 2. (a) View of the left hemisphere, indicating the areas mentioned in the text. (b) Sagittal view of the brain, indicating the areas mentioned in the text.
Adapted from Patrick J. Lynch, medical illustrator, and C. Carl Jaffe, MD, cardiologist.
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to PR was below the fifth percentile of a normal reference group,
and only 38.1% scored higher than the median [20]. This may be
related to the fact that patients referred for PR generally have
moderate to advanced disease. Roncero et al. showed CI in 39.4%
of stable COPD patients. This study was large (N = 940), but it
only assessed cognition using theMini-Mental State Examination
(MMSE) [21], which is useful as a screening tool but not as a
diagnostic tool [22]. Samareh Fekri et al. likewise administered
theMMSE to 87 COPD patients and 60 age- and gender-matched
individuals. MCI was present in 44.8% of patients with COPD and
moderate CI in 6.9%, compared to 33.3% and 3.3%, respectively,
in controls [23]. It is not reported whether these percentages
differ significantly, but the mean MMSE score in the COPD group
was significantly lower than in the control group (22.51 ± 2.4
versus 23.63 ± 2.8, respectively).
Lopez-Torres et al. investigated cognition during hospitaliza-
tion for an exacerbation, at discharge and after return to a stable
state [25]. Cognitive functioning measured by MoCA scores
increased significantly from hospitalization to discharge and
decreased again from discharge to stable state, but to a higher
level than at hospitalization.
In summary, a wide range of prevalences is reported for CI
in COPD. The heterogeneity of applied cognitive tests and cut-
off points to define CI, as well as diverse study populations
(community-dwelling, pulmonary rehabilitation, hospitalized
patients, etc.) likely contributes to this wide range.
3.1.2. Longitudinal studies
Future research using longitudinal designs may elucidate
the development of CI in COPD over several years and the
influence of disease progression and other factors in differ-
ent disease stages. The longitudinal studies already con-
ducted have shown some interesting results. A self-
reported diagnosis of COPD in midlife increased the risk of
developing CI later in life (odds ratio 1.85, 95% CI 1.05–
3.28), but COPD diagnosed later in life was non-significantly
inversely related to CI (odds ratio 0.30, 95% CI 0.08–1.24)
[26]. This surprising result might be explained by survival
bias rather than the effects of COPD itself [26]. In a recent
study, 32.6% of patients taking part in the National
Emphysema Treatment Trial (NETT) were impaired on part
B of the Trail Making Test (TMT) at baseline [27]. This test
measures task switching, which is part of executive func-
tioning. No prevalence estimates were given for subsequent
time points, but TMT-B performance was virtually
unchanged over the 3-year follow-up. Most remarkably,
the sample could be distinguished into four clusters based
on their trajectories of cognitive development over 3 years.
One cluster (35.5%) had low baseline TMT-B scores and
improving scores over time, the second (39.7%) had low
baseline and worsening scores, the third (18.2%) had high
baseline and worsening scores, and the fourth (6.5%) had
high baseline and improving scores.
Table 1. Overview of studies investigating the prevalence of CI in COPD.
Study
(First
author,
year) Country Design Setting Population
Sample
size
Gender
(%
male)
Mean age
(SD)
Cleutjens,
2017a
[18]
Netherlands cross-sectional PR Clinically stable COPD admitted to PR 90 54.4 63.7 ± 8.8
Cleutjens.
2017b
[19]
Netherlands cross-sectional PR Clinically stable COPD admitted to PR 76 60.5 62.7 ± 8.7
non-CI controls with COPD 107 47.7 63.7 ± 9.9
Cleutjens,
2017c
[61]
Netherlands cross-sectional PR Clinically stable COPD admitted to PR 157 50.3 62.9 ± 9.4
Lopez-
Torres,
2016
[25]
Spain longitudinal hospital Patients hospitalized with and recovering from acute COPD
exacerbation
62 75.8 68.32 ± 7.43
Pierobon,
2017
[20]
Italy observational,
cross-
sectional
PR Stable (no exacerbations for the last 3 months) COPD patients
with GOLD stage II-IV, group C-D
84 75.0 70.2 ± 7.0
Park, 2018
[27]
USA observational,
longitudinal
NETT Participants with radiological evidence of bilateral emphysema,
severe airflow obstruction and hyperinflation, and the ability to
complete PR
307 59.6 66.2 ± 5.7
Roncero,
2016
[21]
Spain cross-sectional respiratory
medicine
department
Ambulatory patients > 40 years with stable COPD 940 81.6 67.6 ± 10.0
Samareh
Fekri,
2017
[23]
Iran cross-sectional medical
university
Patients with a history and symptoms of COPD 87 90.8 60.47 ± 9.83
Controls without COPD and CI 60 68.33 58.15 ± 9.8
Note. Studies included in the meta-analysis by Yohannes et al. [17] are not included in this table. PR: pulmonary rehabilitation; COPD: chronic obstructive pulmonary
disease; CI: cognitive impairment; NETT: National Emphysema Treatment Trial; GOLD: Global Initiative for Chronic Obstructive Lung Disease; SD: standard deviation;
MAAS: Maastricht Aging Study; MMSE: Mini-Mental State Examination; MoCA: Montreal Cognitive Assessment; TMTB: Trail Making Test, part B.
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3.2. Cerebral abnormalities
CI is associated with global and/or specific cerebral abnorm-
alities, and many studies have found structural or functional
abnormalities in patients with COPD, along with elevated
serum levels of S100B, a putative marker for brain
damage [28].
Cortical degeneration [29–32], increased occurrence of
small vessel disease [33] or abnormal functional activation on
a global level is uncommon in COPD, with a few exceptions.
Two studies found overall increased white matter (WM) lesion
volumes and decreased WM integrity [30,31], and cortical
thickness and volume were globally reduced in patients who
were hospitalized for 30–45 days following an exacerba-
tion [34].
Regional changes are more common. Gray matter (GM) was
found to be decreased in many brain regions in both hemi-
spheres, among others in the dorsolateral prefrontal cortex
[34], which is involved in higher functions and working mem-
ory [35]; different areas involved in visuospatial processing
[36]; the frontal cortex; and limbic and paralimbic structures
[15,29], which are mainly involved in emotion processing and
memory [37]. Disease duration was inversely related to GM
volume in various, mainly subcortical, regions [12,29], but not
in others, including the hippocampus and amygdala [29].
Reduced WM integrity in the superior and middle frontal
gyri and right occipital subcortical WM was shown in patients
with moderate COPD [32]. WM integrity was more reduced in
the bilateral frontal subcortical areas, right temporal lobe and
pons in severe compared to moderate COPD. Patients with an
acute exacerbation who had been hospitalized for several
weeks also showed reduced WM integrity compared to
healthy controls in various (para)limbic regions [12].
However, Cleutjens et al. [33] showed that cognitively weak
and cognitively strong patients with COPD had equal amounts
of WM hyperintensities (WMH).
Two studies investigated the relation between lung function
and brain volume in healthy elderly. One study reported a signifi-
cant correlation between forced expiratory volume in 1 second
(FEV1) and overall brain atrophy and ventricle-to-brain ratio inmen
but not in women [38]. The FEV1/forced vital capacity (FVC) ratio
was correlated with WMH in the sample as a whole. Participants
with and without chronic respiratory disease did not differ on any
clinical or brain imaging parameter. Moreover, no control variables
were included. The second study only showed a significant posi-
tive relationship between FEV1 and cerebellar WM volume, but no
generalized cortical degeneration [39].
The hippocampus is interesting as it is vital in memory
formation and learning, and only one of the two regions to
display neurogenesis in the adult human brain [40]. As such,
decreased hippocampal volume could also indicate abnorm-
alities in brain plasticity in patients with COPD, but findings
are mixed. In one study, hippocampal volume was decreased
in COPD compared to healthy controls and its size was related
to partial oxygen pressure and oxygen saturation [41].
Hippocampal volume did not differ between patients with
mild-to-moderate COPD and those with severe COPD [41]. In
another study, however, hippocampal volume was not signifi-
cantly different between patients with COPD and controls [42],
and it has also been shown to not differ between cognitively
strong and cognitively weak patients with COPD [33].
Functional abnormalities were reported in the left precentral
and postcentral gyri and the left caudate nucleuswhen comparing
patientswith COPDwith controlsmatched on age, sex, and educa-
tion [14]. Evidence on resting state network and default mode
network activity is mixed. These networks are distinct from others
because their activity increaseswhen thebrain is not engagedwith
other tasks [43]. Their increased activation could hinder cognition
by interferingwith task-related activity. One study found increased
resting-state network activity in patients with COPD compared to
healthy controls, but this result was not significant anymore after
controlling for oxygen saturation [14]. Another study also found
increased default network activation in patients with moderate
COPD but decreased activation in those with severe COPD [44].
This result might reflect a compensatory response to damage
inflicted by factors associated with COPD, and this response
might be strongest in patients with moderate COPD [44].
The structural and functional abnormalities discussed
above reflect a gradual influence of COPD on the brain.
However, COPD can also heighten the risk of more acute
events, such as stroke. This is likely due to high levels of
systemic inflammation and oxidative stress, possibly as a result
of smoking, leading to endothelial dysfunction, decreased
vascular reactivity, thickening of the carotid artery wall and
atherosclerotic plaque rupture [45]. An elevated risk of stroke
in patients with COPD was found in several studies (hazard
ratios [HRs] 1.09 [CI95 0.91–1.31] and 1.24 [CI95 1.19–1.28]
[46,47]) and meta-analyses (HRs 1.30 [CI95 1.09–2.09] [48,49]).
The significance in the latter study was probably due to the
large sample size (N = 132,017 versus 1,566 in the former). HRs
are roughly equal for the ischemic, hemorrhagic, intracerebral,
and subarachnoid hemorrhagic subtypes. However, in the
weeks after an acute exacerbation, the HR increased to 6.66
(CI95 2.42–18.20) [46].
In conclusion, patients with COPD show an increased pre-
valence of many different types of cerebral abnormalities,
compared to healthy controls. Patients with COPD have
reduced gray and WM volume in various brain areas and
WM integrity is compromised. It is still equivocal whether
hippocampal volume is decreased in patients with COPD.
There is evidence for abnormal functional activation, particu-
larly in the resting state and default mode networks. The
abnormalities are spread throughout the brain rather than
concentrated in one or some areas. This could possibly explain
the diffuse pattern of CI found in COPD.
4. CI and health outcomes in COPD
CI has a wide range of adverse effects on self-management skills
and other health outcomes in patients with COPD (see Figure 3).
4.1. Self-management skills
Self-management skills are of major importance for patients
with COPD. Symptoms may vary from day to day and increased
symptoms may be caused by exacerbations. Patients need to
recognize and act upon these exacerbations in an adequate
manner [50]. Moreover, patients need to adhere to their
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medication and need to adopt a healthy lifestyle, including a
healthy diet and physical activity. Smokers need to quit smok-
ing. This often requires a behavior change, which poses a
demand on cognitive functioning [50]. It is therefore feasible
that CI limits the ability to cope with the daily challenges of
living with COPD.
A recent systematic review revealed that there was just one
study in which the impact of CI on self-management skills in
patients with COPD was investigated [51]. This particular study,
including 100 participants with COPD, showed no relationship
between cognitive functioning assessed with the MoCA and
overall self-management abilities, as measured by the Self
Management Ability Score 30 (SMAS30). SMAS30 assesses the
following: taking initiatives, investment behavior, variety, multi-
functionality, self-efficacy, and positive frame of mind. Moreover,
living alone affected the interaction between cognitive function-
ing and self-management abilities [52]. In fact, only among
patients who lived alone, better cognitive functioning was
related to lower self-management abilities [52]. Emotional intel-
ligence (defined as the capacity to understand and manage
personal thoughts and feelings, as well as to positively influence
interpersonal communication and social well-being), however,
seems to be related to self-management abilities in COPD [53].
Meek et al. [54] showed a relationship between MMSE
scores and the ability to accurately recall severity of fatigue
and dyspnea in the previous two weeks. It is reasonable to
assume that this might impact on the ability to recognize and
act upon symptoms of an exacerbation, but the exact relation-
ship remains unknown.
The relationship between CI and inhaler competency is well-
known [51]. An MMSE score of 23–24 points or less is predictive
of poor inhaler technique, as are impaired executive functioning
and impaired praxis. While some inhalers may be more difficult
to use than others, recognizing CI is of major importance when
prescribing inhaler devices as well as providing instructions to
use them [51]. Some studies suggest Turbohalers might be
easier to use for patients with CI than metered dose inhalers
[51,55]. To our knowledge, however, there are no recommenda-
tions specifically on inhaler use for COPD patients with CI.
Nevertheless, inhaler competency is a major consideration
when prescribing inhalers and should be checked regularly.
Brega et al. [56] showed that older persons with impaired
executive functioning were less likely to quit smoking than
those with normal executive functioning. However, recent
data did not confirm the relationship between executive
cognitive dysfunction and smoking cessation [57].
Moreover, another study even showed that persons over
75 years of age who quit smoking had lower cognitive
functioning than persons who continued smoking [58].
Differences in findings about the relationship between
smoking and cognition might be explained by the fact that
patients in the last study were older and different methods
were used to assess cognitive functioning. Cleutjens et al.
did not find a statistically significant difference in smoking
status between patients with COPD entering PR with or
without CI [19]. Therefore, whether and to what extent CI
limits the ability of patients with COPD to quit smoking
remains unclear.
4.2. Health outcomes
CI seems related to functional exercise capacity as measured
by 6-minute walking distance [59,60]. Nevertheless, this was
not confirmed among patients entering PR [19] or during an
exacerbation [59].
Cleutjens et al. showed that the response after completion
of a PR program was similar in patients with CI compared to
those without [61]. However, patients with CI were more likely
to drop out compared to those without CI (23.3% versus
10.3%, respectively). Therefore, timely recognition of CI in
patients entering PR seems paramount.
Several studies showed an inverse relationship between CI
and HRQoL as assessed with the COPD Assessment Test
[21,60], the EuroQoL-5 dimensions questionnaire [21] or St
Figure 3. The possible relationships between cognitive impairment and clinical outcomes. Dotted lines represent conflicting literature concerning the relationship.
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George’s Respiratory Questionnaire [22]. Then again, other
studies did not confirm this relationship [19,62].
The systematic review of Baird et al. included four studies
exploring the relationship between CI and disability and
showed that CI is related to impairment in basic activities of
daily living, instrumental activities of daily living, work, and
social activities [51]. Martinez et al. found that COPD and CI
have independent but additive effects on disability [63].
The co-existence of CI and COPD is associated with a more
than fourfold increased risk of hospitalization for respiratory-
related illnesses and a 34% higher risk of all-cause hospitaliza-
tion compared to healthy controls, after controlling for various
sociodemographic variables, smoking status and comorbid-
ities [64]. Moreover, CI seems to be related to an increased
length of hospitalization [22]. Data from the NETT trial did not
show an association between impairment in executive func-
tioning and frequency of hospitalization [65].
A study including stable patients with COPD even showed
that drawing impairment predicted increased mortality risk
[66]. Nevertheless, Yohannes et al. found that MMSE scores
did not predict 1-year all-cause mortality [67]. Moreover, only a
modest association was found between executive function
and survival in the NETT trial [65].
In conclusion, CI may negatively impact self-management
and health outcomes in COPD, but the current literature is
conflicting and many questions remain. The conflicting litera-
ture may be explained by different methods used to assess
cognitive functioning and criteria used to define CI. Moreover,
there were major differences between the studied popula-
tions. The complex cause–effect relationships also make this
field very challenging. COPD may influence self-management
skills, but poor self-management in turn also worsens COPD
disease progression, thereby creating a vicious cycle.
5. Determinants of COPD-induced cognitive
impairment
Factors such as hypoxemia, hypercapnia, inflammation, and
lifestyle factors may all contribute to structural and functional
cerebral abnormalities and CI. Any individual factor probably
does not explain a significant amount of CI, but their syner-
gistic effects may be large [11,68].
5.1. Hypoxemia and hypercapnia
Hypoxemia and hypercapnia are hallmarks of severe COPD
[69] which can also negatively affect cognition [70,71].
Hypoxemia alters the microenvironment around neurons [72]
and induces impairments in spontaneous and task-stimulated
neuronal activity [73,74]. Hypoxemia might underlie decreases
in GM density [12,15], and mild hypercapnia decreases func-
tional connectivity in almost all brain lobes [75]. The exact
mechanisms through which this happens are still unclear [75].
Diminished vasodilatation in response to hypoxemia or hyper-
capnia in patients with COPD might be one [76].
5.2. Inflammation
Multiple lines of evidence indicate that systemic inflammation
might underlie CI in COPD. Low-grade systemic inflammation
is linked to decreased cognition in other conditions including
obesity [77,78] and metabolic syndrome [79,80]. In the general
population c-reactive protein (CRP) and interleukin-6 levels
were related to global cognition and executive functioning,
whereas α1-antichymotrypsin was not [81]. MoCA scores have
been found to be negatively correlated with CRP, fibrinogen,
and erythrocyte sedimentation rate levels [82]. The relation-
ship between inflammation and cognition in stable COPD has
not been thoroughly investigated yet. Next to low-grade sys-
temic inflammation, patients with COPD may experience per-
iods of an enhanced systemic inflammatory response related
to disease exacerbations that will be discussed later.
5.3. Respiratory medication
Long-acting beta-adrenoreceptor agonists (LABA), long-acting
muscarinic antagonists (LAMA) and inhaled corticosteroids are
frequently prescribed to patients with COPD [1].
Some literature has associated anticholinergic use with
increased risk of MCI [83] and dementia [83–85], and faster
cognitive decline [86]. However, participants in these studies
used systemic rather than inhaled medication. Inhaled medi-
cation is much more targeted and will therefore have much
less systemic effects. For example, tiotropium cannot cross the
blood-brain barrier [87] which might suggest no or limited
effect on cognitive functioning. However, no studies have
investigated the effects of tiotropium on cognition yet.
The effects of corticosteroids or glucocorticoids (GC) on
cognition have not been investigated in patients with
COPD yet either. In general, mildly elevated GC levels
improve cognition [88], but long-term administration can
cause ‘steroid dementia’, characterized by impairments in
episodic, declarative and working memory and executive
function, and associated hippocampal and prefrontal dys-
function [89]. Steroid dementia can appear within weeks of
commencing GC treatment and is largely reversible upon
its termination, although impairments can remain for years
after termination [89,90].
It is doubtful whether steroid dementia is a real risk in
COPD. The recommended dose and duration for patients
with an acute exacerbation (30–40 mg of prednisone daily
for 7–14 days, where 5 days may be equally effective [91])
are much lower and shorter than those reported to cause
steroid dementia (i.e., 60 mg/day for 7 months [90] or
40–60 mg/day for 37 days [92]).
In conclusion, to date, evidence that respiratory medication
can contribute to impaired cognition in patients with COPD is
lacking.
5.4. Exacerbations
During acute exacerbations, the above-mentioned determi-
nants intensify and converge. Interestingly, exacerbations
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have an additional detrimental effect on cognition
[22,82,93,94]. During acute exacerbations, levels of inflamma-
tion and cognitive functioning are inversely related [95], and
as recovery from exacerbation-related CI seems very slow to
non-existent, it can be speculated that regular COPD exacer-
bations can trigger a stepwise decrease in cognition. One
study found no improvement in the 3 months after an exacer-
bation [22]. However, because these patients were not cogni-
tively tested prior to the exacerbation, it cannot be
determined whether the exacerbation actually affected cogni-
tion in this study.
5.5. Comorbidities
COPD often presents with comorbid conditions such as
obstructive sleep apnea (OSA), depression and chronic heart
failure (CHF), and a recent systematic review reported an
increased risk prevalence of the metabolic syndrome in
COPD compared to matched controls [96].
OSA contributes to decreased arterial oxygen saturation
[97], causes sleep fragmentation and cortical and sympathetic
arousal [97,98], and affects attention, memory, psychomotor
speed, visuospatial abilities, constructional abilities, executive
functions, and language abilities [97,99]. Hypoxemia, a shared
component between OSA and advanced COPD, might under-
lie the cognitive deficits apparent in both diseases, namely
attention, memory, executive function, psychomotor function,
and language abilities [99].
Depression is associated with decreased cognitive func-
tioning [100] in COPD, but it probably only predicts 1–2% of
the variation in cognition [3]. A study investigating cogni-
tive bias in patients with COPD and healthy controls with
and without depression revealed that depressed patients
with COPD showed a comparable pattern of bias compared
to depressed healthy controls, whereas never-depressed
patients showed much less bias [101]. In conclusion, the
influence of concurrent COPD and depression on cognition
is still equivocal.
Many patients with COPD also suffer from CHF, and vice
versa [17]. The prevalence of CI in CHF is largely unknown, as
prevalence estimates between 13.5% and 80% have been
reported [17]. CHF and COPD might have additive effects on
cognition. Moreover, COPD and CHF are both associated with
a high prevalence of cerebrovascular diseases, which could
lead to chronic cerebral hypoxia, impaired brain perfusion
and ultimately brain damage and cognitive impairment [17].
Furthermore, etiological similarities, such as cigarette smoking,
may lead to a common set of symptoms, including CI [17].
Metabolic syndrome (MetS) is a cluster of metabolic risk
factors, such as central obesity, dyslipidemia, hyperglycemia
and dyslipidemia [96], with a prevalence of 34% in patients
with COPD [96]. MetS is strongly related to the risk of devel-
oping type 2 diabetes and cardiovascular disease [96] and has
also been shown to have a deleterious influence on cognition
[102,103]. However, some research also suggests that certain
components of MetS have a larger effect than others
[104,105]. It is yet unclear what the relative contribution of
each of the components of MetS on cognition is.
5.6. Smoking
Smoking is one of the largest risk factors for developing lung
cancer or COPD, and it affects cognition in multiple ways. Firstly,
it increases carbon monoxide and carbon dioxide levels in the
blood, causing hypercapnia [106] and hypoxemia [107], respec-
tively. Secondly, cigarette smoke contains many neurotoxic com-
ponents, such as cadmium, nitric oxide and lead [108]. Thirdly, the
many free radicals in cigarette smoke are neurotoxic [109]. And
finally, chronic nicotine administration increases tau phosphoryla-
tion, a key component of Alzheimer’s disease pathophysiology
[108], and induced free radical production and depleted antiox-
idant levels in a rat model [110]. Ultimately, all of these compo-
nents cause decreased GM andWM volume and connectivity, and
impair cognition [111–113].
Only one study investigated the influence of smoking on CI
specifically in patients with COPD [114]. Cognitive perfor-
mance of patients with COPD was comparable to that of
smokers, but both were significantly worse compared to nor-
mal reference values. The number of pack-years and the dura-
tion of abstinence of the past smokers, consisting almost two-
thirds of the sample, was not reported. Therefore, it cannot be
determined with certainty to which degree smoking affects
cognition beyond the effects of COPD. In general, smoking per
se contributes to cognitive dysfunction, but there is also evi-
dence of a relationship between impaired lung function and
cognition independent of smoking [3,115].
5.7. Dietary insufficiencies
Diet and nutritional habits significantly impact on brain fitness,
mental and cognitive health throughout life [116,117]. The
relative abundance of specific dietary nutrients, depending
on intake, bioavailability and metabolism, affects mental
health and cognitive ability via direct and indirect mechanisms
that modulate neuronal function and synaptic plasticity [118].
Chronic stress has been shown to negatively impact on brain
plasticity and cognitive performance, for instance through the
harmful effects of cortisol [119–121] and poor dietary habits
are hypothesized to correlate with heightened stress reactivity
and susceptibility [122] and greater cognitive decline in elderly
[123]. A healthy diet, rich in polyphenols, B vitamins, polyun-
saturated fatty acids, and dietary fibers exert favorable effects
on cognitive performance, stress reactivity, and neuroinflam-
mation [118,124]. Unintended weight loss and muscle wasting
are common in advanced COPD, but specific nutritional defi-
ciencies that could affect cognition have received limited
attention to date. However, next to disease severity, Collins
et al. recently highlighted in a UK COPD population the impor-
tance of deprivation on malnutrition risk [125]. An Australian
study reported, next to low muscle mass, a high prevalence of
deficiencies in vitamin D, vitamin B12 and iron in patients with
COPD hospitalized with an acute exacerbation [126]. A Dutch
study investigating patients eligible for PR reported that vita-
min D and calcium intake were below the recommended
levels in more than 75% of patients, whereas vitamin A, C
and E intakes were below the recommended levels in over
one-third of patients [127]. No studies have yet investigated
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the relationship between nutritional status or dietary pattern
and cognitive performance in COPD.
5.8. Inactive lifestyle
Higher levels of physical activity are associated with a reduced
risk of cognitive decline and dementia [128]. However, dis-
ease-related factors such as dyspnea and muscular metabolic
abnormalities make it hard for many patients with COPD to be
physically active. One systematic review found a mean daily
step count of 2,237 [129], which is far less than the threshold
for a low active (5,000 steps) or active lifestyle (10,000 steps)
indicated by the same authors [129]. Low physical activity
levels and a sedentary lifestyle negatively impact on cognition
in the general population [130,131], and as such may contri-
bute to CI in COPD as well.
Overall, disease-specific as well as lifestyle factors may
contribute to the development of CI in COPD, but the relative
potential synergistic contributions of the individual factors are
yet unclear.
6. Possible future interventions
6.1. Cognitive training
Cognitive training can improve cognitive functioning in
healthy elderly adults [132,133], and can also improve some
cognitive domains in those with MCI [132]. Research into
cognitive training specifically for patients with COPD is scarce.
One trial attempted to ameliorate cognition in hypoxemic
patients with COPD through an intervention aimed at improv-
ing attention, learning, and logical-deductive thinking [134].
During the first 2 weeks, the intervention group received
group cognitive training, in the four weeks thereafter they
received individual training, followed by home assignments
two times per week. Booster sessions took place after 3 and
5 months. The control group received usual care and no
cognitive training. Some cognitive domains improved in
both the intervention and placebo group, but the intervention
had no additional effect on cognition.
6.2. Exercise training
Exercise can improve cognition through multiple pathways. It
causes an increase in cerebral blood flow [38] and levels of
cerebral growth factors such as brain-derived neurotrophic factor
[135] and insulin growth factor-1 [136]. These growth factors are
involved in many functions which are important for cognition.
They influence the rate of differentiation and apoptosis of cere-
bral cells [137] and regulate long-term potentiation [138] and
hippocampal neurogenesis [137]. Multiple previous studies have
shown the benefit of exercise on cognition in COPD patients
[139,140], and in the study by Park et al. the 6-minute walking
distance was the only potentially modifiable variable that was
related to worsening cognitive functioning over time [27]. The
question remains, however, whether these improvements con-
solidate into the longer term if exercise is discontinued [11].
6.3. Smoking cessation
Given the deleterious influences of smoking on cognition, it is
unsurprising that smoking cessation is beneficial. However, its
effects on cognitive functioning have only been assessed in
the general population. It appears that the number of pack-
years negatively affects cognitive functioning, but also that
cognitive functioning improves with longer duration of absti-
nence [141]. This implies that abstinence pays off at any age,
with the largest benefits coming to those who stop the ear-
liest. Future research should further investigate the effects of
smoking cessation on cognition in COPD in more detail.
6.4. Dietary intervention
Dietary intervention may imply adopting a different dietary
pattern or supplementing the habitual diet with specific nutri-
ents. The Mediterranean diet, the Dietary Approach to Stop
Hypertension (DASH) diet and the Mediterranean-DASH
Intervention for Neurodegenerative Delay (MIND) diet have
been proposed as beneficial to cognition [142–144]. Drastic
dietary changes, however, are not likely to be feasible for
patients with advanced COPD.
These interventions imply that CI in COPD is not something
that patients have to passively undergo, but can be readily
applied in daily life. However, more research is needed to
assess the feasibility and efficacy of the individual interven-
tions or multimodalities thereof.
7. Conclusion
CI in patients with COPD is a problem with a high prevalence
and large consequences, yet it is still under-recognized and
under-investigated. More research aimed at unraveling the
etiology and appropriate interventions to diminish cognitive
decline or treat CI in patients with COPD is needed to benefit
the patients as well as their loved ones.
Caregivers should pay more attention to potential CI in their
patients, as CI may have large consequences on self-manage-
ment and health outcomes. In a clinical context, administering a
brief screening tool may help in identifying patients who need
referral to a specialist for further investigation. These patients
also need more time and attention, for instance, while making
sure they understand how to properly use their medication.
8. Expert commentary
Technical developments in the field of cognitive neuroscience
enable more detailed insight in the pathophysiology of CI in
COPD. Increasing magnetic resonance imaging resolution allows
a more detailed picture of the brain, techniques such as diffusion
tensor imaging allow focusing specifically on WM instead of the
brain as a whole, and shorter and more effective scanning pro-
tocols can make brain imaging more accessible and affordable.
Investigating novel research directions might also be
worthwhile. For instance, the synthesis and proper functioning
of many neurotransmitters, including the catecholamines, glu-
tamate, aspartate, and perhaps most importantly acetylcholine
(as it is widely available in the brain but also the most
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important neurotransmitter in the airways) depend on oxygen
availability [145]. Hypoxia-based neurotransmitter abnormal-
ities might therefore constitute a third type of cerebral
abnormality contributing to CI, next to structural and func-
tional abnormalities. However, this has received scarce
research attention to date in the general population, and
especially in COPD.
Longitudinal studies are essential for understanding the
causes and consequences of CI in COPD. They can elucidate
the development of cognitive decline in COPD in relation to
the development of other potentially relevant variables such
as impaired lung function, hypoxia or inflammation. In this
way, the relative contributions of disease- and aging-related
factors can also be further disentangled.
Interesting treatment options for CI in COPD include the
potential role of specific nutrients in ameliorating cognition.
The Mediterranean diet, which is characterized by a high
intake of plant-based foods, moderate-to-high fish and sea-
food consumption and scarce use of dairy products and meat
[142], has earlier been shown to improve cognition in a ran-
domized controlled trial [142]. Furthermore, polyunsaturated
fatty acids and polyphenols can ameliorate cognition and
have a positive effect on various neurobiological processes
[146]. Also, testing potential synergistic effects of combina-
tions of interventions could be worthwhile, such as exercise
training and cognitive training.
An important prerequisite for all the above research ques-
tions is the choice of the right cognitive test instruments.
Often applied screening tools such as the MMSE or MoCA
can be useful in a clinical setting to identify patients in need
of further neuropsychological assessment and therapy, but
cannot give a detailed overview of the exact nature of a
person’s deficits. Larger, well-defined and evidence-based
test batteries are essential in order to get a comprehensive
overview of a person’s neuropsychological functioning [147].
9. Five-year view
In conclusion, it is important to further investigate the patho-
physiology, causes and consequences of CI in COPD in the next 5
years, and to develop tailored intervention strategies.
Developments in the fields of cognitive neuroscience and neu-
ropsychology will enable a more detailed picture of the patho-
physiology of CI in COPD. Longitudinal studies can pinpoint its
determinants and identify its consequences, and much work
remains to be done in finding (the most) effective treatments.
Key issues
● Cognitive impairment is an important extra-pulmonary fea-
ture of COPD
● Awide range of cognitive functions are affected in patientswith
COPD, such as memory and various executive functions
● Cognitive impairment has a high prevalence in patients
with COPD and is more common in patients with COPD
than in age-matched controls.
● Many factors can contribute to the development of brain
damage and cognitive impairment in COPD, such as
smoking, hypoxemia, inflammation, different comorbidities,
dietary insufficiencies, medication use and lack of activity.
● Cognitive impairment has large negative consequences on
health outcomes of patients with COPD, including
hospitalization.
● Interventions such as exercise training, smoking cessation
and dietary improvement are promising to prevent or treat
(mild) cognitive impairment.
Future research should focus on investigating aspects such as
the longitudinal development of cognitive impairment in COPD
and the efficacy of various interventions to prevent and treat it.
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